Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Trimmed by Nissay Asset Management Corp Japan ADV

Nissay Asset Management Corp Japan ADV decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,696 shares of the medical research company’s stock after selling 364 shares during the period. Nissay Asset Management Corp Japan ADV’s holdings in Thermo Fisher Scientific were worth $27,196,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Nomura Holdings Inc. increased its stake in Thermo Fisher Scientific by 179.1% during the 4th quarter. Nomura Holdings Inc. now owns 15,427 shares of the medical research company’s stock valued at $8,026,000 after buying an additional 9,899 shares during the period. Nearwater Capital Markets Ltd acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $10,405,000. NorthRock Partners LLC increased its stake in Thermo Fisher Scientific by 32.5% during the 4th quarter. NorthRock Partners LLC now owns 4,458 shares of the medical research company’s stock valued at $2,319,000 after buying an additional 1,093 shares during the period. Minot DeBlois Advisors LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $46,000. Finally, Mmbg Investment Advisors CO. grew its stake in shares of Thermo Fisher Scientific by 1.3% in the 4th quarter. Mmbg Investment Advisors CO. now owns 14,501 shares of the medical research company’s stock worth $7,544,000 after purchasing an additional 185 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $428.88 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $401.75 and a 12-month high of $627.88. The stock has a market capitalization of $161.90 billion, a PE ratio of 25.95, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average price of $460.85 and a two-hundred day moving average price of $513.11.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the firm posted $5.11 earnings per share. The company’s quarterly revenue was up .2% compared to the same quarter last year. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a $0.43 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Analyst Ratings Changes

Several brokerages have recently issued reports on TMO. Scotiabank lowered their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a research note on Friday, April 25th. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. StockNews.com cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Friday, April 25th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Finally, Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $607.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.